Lupin has got the US health regulator’s final approval for marketing its Desoximetasone cream that is used in treating skin disease in the American market.

Lupin has said in a BSE filing that it “has received final approval for its Desoximetasone cream USP, 0.05 percent and Desoximetasone cream USP, 0.25 percent from the United States Food and Drug Administration (USFDA).”

It added that the products to be marketed are generic versions of Taro’s Topicort LP Emollient cream, 0.05 percent and Topicort cream, 0.25 percent.

Read EquityPandit’s Technical Analysis on Nifty Pharma